The use of four-drug combination chemotherapy (D.A.V.E.) in the treatment of advanced Wilms' tumour
| Autor: | J E Freeman, A. G. Stansfeld, James S. Malpas, J. R. Graham-Pole, David B. Dunger, M. R. Sandland |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Vincristine Time Factors Adolescent Cyclophosphamide Antineoplastic Agents Toxicology Wilms Tumor Pharmacotherapy Recurrence Internal medicine Humans Medicine Pharmacology (medical) Doxorubicin Stage (cooking) Child Pharmacology business.industry Infant Wilms' tumor Combination chemotherapy medicine.disease Kidney Neoplasms Surgery Child Preschool Toxicity Dactinomycin Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 5:211-215 |
| ISSN: | 1432-0843 0344-5704 |
| DOI: | 10.1007/bf00434386 |
| Popis: | A study was begun in 1971 at St. Bartholomew's Hospital with a combination of 4 drugs, dactinomycin (actinomycin D), adriamycin, vincristine and Endoxan (cyclophosphamide) (D.A.V.E.), together with surgery and radiation, in the treatment of stage III and stage IV Wilms' tumour. Seventy-one percent of the children treated achieved complete response. The median survival from diagnosis was 19 months, and in those children achieving complete response the median disease-free survival has not yet been reached. Toxicity was not a serious problem. The study group is compared with a group of children treated at this hospital before 1971. There is an improved survival in the children treated with D.A.V.E. Children who have relapsed with stage I or stage II disease may also respond. This four-drug combination was well tolerated and effective, and confirms recent experience suggesting that intensive multiple-drug regimens may be curative even in advanced disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink